News
LXRX
2.190
+10.61%
0.210
Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
LuxUrban Hotels shares dipped 27.4% to $1.5523 on Wednesday. The company issued preliminary fourth-quarter revenue outlook below estimates. MariaDB plc shares climbed 70.4%. Lixte Biotechnology Holdings, Inc. Shares jumped 68.6% in mid-day session.
Benzinga · 15h ago
Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday
Shares of Cintas Corporation jumped 9.7% to $694.62 on Wednesday. The company reported better-than-expected third-quarter financial results and raised FY24 guidance. PaySign, Inc. Shares jumped 28.2% after the company announced better- than-expected fourth-quarter results. Dow Jones index gained around 300 points in Wednesday's session.
Benzinga · 18h ago
WPRT, FIVN and FATE are among after hour movers
On the Move WPRT, FIVN and FATE are among after hour movers. Stoke Therapeutics (STOK) and AnaptysBio (ANAB) are among the Gainers. Westport Fuel Systems (WPRT) and Five9 (FIVN) are losers.
Seeking Alpha · 2d ago
Lexicon Pharmaceuticals files to sell 57.66M shares for holders
Lexicon Pharmaceuticals files to sell 57.66M shares for holders Mar. 25, 2024. The company filed a prospectus related to the proposed resale of 57. 66M shares by selling stockholders. This prospectus is not an offer to sell these securities.
Seeking Alpha · 2d ago
Lexicon Pharmaceuticals Announces Clinical Data On The Impact Of Sotagliflozin On Stroke And Heart Attack Risk Among Four Lexicon-Sponsored Presentations At The American College Of Cardiology 73rd Annual Scientific Session & Expo
Four data presentations related to sotagliflozin, an inhibitor of two sodium glucose transport proteins, will be delivered during the American College of Cardiology 73rd Annual Scientific Session & Expo in Atlanta, 2024. The presentations include results from a post-hoc evaluation of the efficacy of the drug in reducing stroke events in patients with type 2 diabetes, chronic kidney disease and high cardiovascular risk.
Benzinga · 2d ago
Weekly Report: what happened at LXRX last week (0318-0322)?
Weekly Report · 2d ago
Weekly Report: what happened at LXRX last week (0311-0315)?
Weekly Report · 03/18 09:23
Analysts’ Top Healthcare Picks: REPRO-MED Systems (KRMD), Catalyst Pharma (CPRX)
TipRanks · 03/14 11:20
Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
NASDAQ · 03/13 16:45
Lexicon stock slides 8% after rallying 30% in prior session
Lexicon Pharmaceuticals stock slides 8% after rallying 30% in prior session. The company's drug sotagliflozin showed improved glycemic control in patients with type 1 diabetes and chronic kidney disease. Lexicon plans to resubmit its market application to the FDA for the drug in mid-2024.
Seeking Alpha · 03/12 15:38
Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis Of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment In Patients With Type 1 Diabetes And Chronic Kidney Disease
Lexicon Pharmaceuticals says treatment with sotagliflozin resulted in improved glycemic control in patients with type 1 diabetes and chronic kidney disease. The drug lowered A1C, body weight and systolic blood pressure with safety similar to the total study cohort. The efficacy and safety data were presented last week at ATTD 2024.
Benzinga · 03/12 12:06
ACADIA Pharmaceuticals, Ocular Therapeutix, Asana And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
ACADIA Pharmaceuticals Inc shares fell sharply in today’s pre-market trading. The company reported the Phase 3 ADVANCE-2 trial of its schizophrenia drug did not meet the primary endpoint. The Nasdaq futures were mixed this morning. Power & Digital Infrastructure Acquisition II Corp. Shares tumbled 181% on Monday.
Benzinga · 03/12 09:36
Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset
Seeking Alpha · 03/12 07:57
Lexicon Pharmaceuticals GAAP EPS of -$0.20 in-line, revenue of $0.7M misses by $1.24M
Lexicon Pharmaceuticals' Q4 GAAP EPS of -$0.20 in-line, revenue of $0.7M misses by $1.24M. Shares of the company fell 3.91% in after-hours trading. The company had $170.0 million in cash and investments as of December 31, 2022.
Seeking Alpha · 03/11 20:51
Dow Turns Higher; GDS Holdings Shares Climb
U.S. Stocks traded mixed on Monday, with the Dow Jones index turning higher. The Dow traded up 0.08% to 38,753.49 while the NASDAQ fell 0.20%. Materials shares jumped by 0.9% on Monday; industrials shares fell by0.8%. Asian markets closed mixed while European shares were mostly lower.
Benzinga · 03/11 18:44
BUZZ-U.S. STOCKS ON THE MOVE-Acelyrin, Endeavour Silver, B2Gold
Wall Street's main stock indexes slipped on Monday. The Dow Jones Industrial Average was up 0.05% and the S&P 500 was down 0.16%. Investors are awaiting key inflation data this week. Acelyrin, Endeavour Silver, B2Gold rise.
Reuters · 03/11 18:18
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Mesoblast shares jumped 13.4% to $2.4399 on Monday. The company announced FDA support of an accelerated approval pathway for end-stage heart failure patients. Kidpik Corp. Shares gained 238% in today's mid-day session.
Benzinga · 03/11 17:41
Crude Oil Edges Higher; Lexicon Pharmaceuticals Shares Jump
U.S. Stocks traded lower midway through trading on Monday, with the Dow Jones index dipping over 50 points. The Dow traded down 0.16% to 38,662.09 while the NASDAQ fell 0.26%. Materials shares jumped by 0.3% on Monday; industrials shares fell by 1.1%. Asian markets closed mixed; European shares were mostly lower.
Benzinga · 03/11 16:15
Lexicon stock rallies 18% amid FDA update, $250M private placement
Seeking Alpha · 03/11 16:15
Lexicon Pharmaceuticals GAAP EPS of -$0.20 beats by $0.02, revenue of $0.7M misses by $0.54M
Lexicon Pharmaceuticals, Inc. GAAP EPS of -$0.20 beats by $0.02, revenue of $ 0.7M misses by $.54M. Q4 GAAP revenue for the company was $1.2 million. The company's stock is down 2.7% in the last month.
Seeking Alpha · 03/11 16:13
More
Webull provides a variety of real-time LXRX stock news. You can receive the latest news about Lexicon Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About LXRX
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its pipeline includes Sotagliflozin, LX9211, and LX2761. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. Its LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of SGLT2 in the kidney.